Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.66) by 65.15 percent. This is a 8 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $162.910 thousand which beat the analyst consensus estimate of $150.000 thousand by 8.61 percent. This is a 93.87 percent decrease over sales of $2.656 million the same period last year.